Teva Pharmaceutical Industries Q3 Adjusted Earnings Rise, Revenue Falls; Raises 2026 Guidance

07:17 AM EST, 11/03/2026 (MT Newswires) -- Teva Pharmaceutical Industries (TEVA) reported Q3 adjusted earnings Tuesday of $0.86 per diluted share, compared with $0.78 a year earlier. Analysts polled by FactSet expected $0.72. Net revenue for the quarter ended Sept. 30 was $4.40 billion, down from $4.48 billion a year earlier. Analysts expected $4.23 billion. Teva increased the lower end of its full-year adjusted EPS guidance to $1.92 to $2.11 from $1.91 to $2.11. Analysts expect $2.03. The company raised its 2026 revenue guidance to $16.7 billion to $17 billion, from its previous outlook of $16.5 billion to $16.85 billion. Analysts expect $16.59 billion. Shares of the company were up 1.5% in Tuesday premarket activity.